Canopy and Texas Oncology Announce Multi-Year Partnership to Improve Patient Outcomes

NEW YORK, March 18, 2025 /PRNewswire/ -- Canopy, the first Continuous Care Platform for oncology, today announced a multi-year partnership with Texas Oncology, one of the nation's largest community-based oncology practices, encompassing nearly 1,000 providers across 280 locations in Texas. Building on the success of an initial pilot at Texas Oncology's Amarillo Cancer Center, the collaboration will extend Canopy's advanced platform to deliver enhanced, proactive care for patients across the Texas Oncology Network.

"We have observed a positive impact on both patient outcomes and operational efficiency from Canopy."

"Oncologists are seeing the fastest rate of therapeutic innovation in history. With this growing complexity, our practice must also evolve," said R. Steven Paulson, MD, President and CEO of Texas Oncology. "This partnership with Canopy ensures that we remain at the forefront of cancer care, allowing us to set new standards in our approach to each patient's unique journey."

Debra Patt, MD, PhD, MBA, Executive Vice President of Public Policy and Strategy for Texas Oncology, added, "Oncology practices today encounter significant hurdles in expanding care outside the clinic—from technology limitations to interoperability challenges and reimbursement constraints. We have observed a positive impact on both patient outcomes and operational efficiency from Canopy. By leveraging Canopy's AI-native automation and clinical decision support tools, we aim to improve care delivery while easing the administrative burden on our teams."

Presentations highlighting the potential impact of Canopy's platform on oncology patient experience in real-world settings have demonstrated:

• 45% improvement in treatment persistence at three months¹ [ASCO, 2022]
• 22% reduction in ER visits/hospitalizations per 100 patient months² [ASCO, 2022]
• 88% patient engagement sustained at six months³ [JCO, 2022]

Most recently, at the 2024 American Society of Hematology (ASH) meeting, Canopy presented new data highlighting:

• 37% reduction in treatment discontinuation at three months⁴ [ASH, 2024]
• Improved early detection of toxicities with bispecific antibody therapies⁵ [ASH, 2024]

Canopy supports care teams by capturing any issues patients might be experiencing between visits, streamlining care to drive rapid issue resolution, and enabling the capture of meaningful reimbursement through programs like Principal & Chronic Care Management (PCM/CCM) and Remote Therapeutic Monitoring (RTM).

To ensure a seamless experience between the systems care teams use daily, Canopy has also integrated with iKnowMed, Ontada's award-winning electronic health record (EHR), by becoming a member of the Ontada Developer Marketplace. Part of McKesson's suite of oncology solutions, Ontada enhances clinician experiences with innovative EHR technology and an open ecosystem.

"Partnering with Texas Oncology is a pivotal step in our mission to make continuous care the standard for all patients with cancer," said Lavi Kwiatkowsky, CEO and Founder of Canopy. "Texas Oncology's forward-thinking approach and dedication to embracing innovation make them an ideal partner. Together, we aim to set a new benchmark for AI-powered, continuous oncology care."

About Canopy

Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy's multi-channel ePRO and remote triage system enables practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from programs like RTM, PCM, CCM, EOM and more. For more information, visit www.canopycare.us.

About Texas Oncology

With more than 530 physicians and 280 locations, Texas Oncology is an independent private practice that sees more than 71,000 new cancer patients each year. Founded in 1986, Texas Oncology provides comprehensive, multi-disciplinary care, and includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Colon & Rectal Specialists, Texas Oncology Surgical Specialists, Texas Urology Specialists, and Texas Imaging and Infusion Center. Texas Oncology's robust community-based clinical trials and research program has contributed to the development of more than 100 FDA-approved cancer therapies. Learn more at TexasOncology.com.

About Ontada^®

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit ontada.com.

Media Contact:

Kaitlin Hemric
Canopy
704-838-6168
kaitlin@canopycare.us

¹ Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528

² Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508

³ Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180

⁴ Essell, J. H., Derman, B. A., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 8). Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. American Society of Hematology Annual Meeting

⁵ Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting

View original content to download multimedia:https://www.prnewswire.com/news-releases/canopy-and-texas-oncology-announce-multi-year-partnership-to-improve-patient-outcomes-302403475.html

SOURCE Canopy